Filing Details
- Accession Number:
- 0000899243-19-026672
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-05 16:05:54
- Reporting Period:
- 2019-11-01
- Accepted Time:
- 2019-11-05 16:05:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1629137 | Global Blood Therapeutics Inc. | GBT | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1238408 | Borga Tricia Suvari | C/O Global Blood Therapeutics, Inc. 171 Oyster Point Blvd., Suite 300 South San Francisco CA 94080 | Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2019-11-01 | 1,127 | $48.68 | 12,386 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-11-01 | 2,200 | $48.33 | 10,186 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- Represents the weighted average sale price of the shares sold ranging from $48.57 to $48.84 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- Represents the weighted average sale price of the shares sold ranging from $47.57 to $48.56 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.